Advisory board · Dr. William Abbott

• Comparator checkpoint monotherapy
• Duration of response
• Brain-metastasis subgroup data

• irAE management guide
• PD-L1 testing pathway infographic

1. What was the median PD-L1 testing turnaround in the pivotal trial sites?
2. Is there subgroup data for patients with untreated brain metastases?

Advisory board with radiation oncologist at Universitätsklinikum Heidelberg. Discussed comparator checkpoint monotherapy, duration of response, brain-metastasis subgroup data.